We are pioneers in harnessing bacteria as a novel and revolutionary class of medicines: Live Biotherapeutics
We understand that bacteria in the human intestine - known as the gut microbiome - have an important function in many diseases.
Importantly, we understand how they function and how they could be used as a revolutionary new class of medicines known as Live Biotherapeutic Products (LBPs).
Our deep understanding of bacterial functionality enables us to develop Live Biotherapeutics for a large number of diseases including cancer, gastrointestinal disease, respiratory disease and central nervous system disease.
What makes 4D pharma different?
We understand that the bacteria of the gut microbiome have an important function in health and disease, but importantly – we understand how they function, and how they could be used as potential new therapies.
Watch our video below to find out more about our approach.
4D and the Live Biotherapeutics we develop have the potential to transform he way in which many challenging diseases are treated.
What sets us apart?
- We are targeting a new, safer approach to drug development
- We are a fully integrated microbiome company with the capability to progress from research to production to clinic
- We understand mechanism: how our products exert their therapeutic effects and act as a drug
- We have developed and wholly own the largest intellectual property estate in the field
We have laid foundations that have positioned 4D to transform the sector; with four clinical programs delivering data and a number of development programs in exciting new areas progressing towards the clinic, 4D pharma is taking the lead in defining the microbiome space.